Lung cancer vaccines

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 302-308

  Kelly, Ronan J ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Lung cancer; vaccines

Indexed keywords

BELAGENPUMATUCEL L; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IDM 2101; MELANOMA ANTIGEN 3; MUCIN 1; PLACEBO; TRANSFORMING GROWTH FACTOR BETA2; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

CANCER STAGING; CELL SUSPENSION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW;

ANTIGENS, CD146; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; EPIDERMAL GROWTH FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MUCIN-1; OLIGONUCLEOTIDES, ANTISENSE; TRANSFORMING GROWTH FACTOR BETA2;

EID: 80053369273     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318233e6b4     Document Type: Review

References (73)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-594. (Pubitemid 351720831)
3. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall- cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409-417; discussion 417-418.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103. (Pubitemid 30324363)
5. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2(4 suppl 1):S161-S168.
6. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27:129-139.
7. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276. (Pubitemid 34441324)
8. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem. 2001;276:20809-20812.
9. Neuner A, Schindel M, Wildenberg U, et al. Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer. 2002;101:287-292. (Pubitemid 34970898)
10. Fontana A, Frei K, Bodmer S, et al. Transforming growth factorbeta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol. 1989;143:3230-3234. (Pubitemid 20010150)
11. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986;136:3916-3920. (Pubitemid 16122096)
12. Tsunawaki S, Sporn M, Ding A, et al. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988;334:260-262.
13. Dermime S, Armstrong A, Hawkins RE, et al. Cancer vaccines and immunotherapy. Br Med Bull. 2002;62:149-162. (Pubitemid 34832477)
14. Nencioni A, Gruenbach F, Patrone F, et al. Anticancer vaccination strategies. Ann Oncol. 2004;15(suppl 4):iv153-iv160. (Pubitemid 39585328)
15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252. (Pubitemid 28155090)
16. Lechler R, Chai JG, Marelli-Berg F, et al. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology. 2001;103:262-269. (Pubitemid 32626175)
17. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323-370. (Pubitemid 34293428)
18. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71:907-920.
19. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25: 267-296. (Pubitemid 46697910)
20. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369-380. (Pubitemid 41579832)
21. Yasumoto K, Hanagiri T, Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against nonsmall- cell lung cancer. Gen Thorac Cardiovasc Surg. 2009;57: 449-457.
22. Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin Med Res. 2005;3:221-228.
23. Sporn MB, Roberts AB, Wakefield LM, et al. Transforming growth factor-beta: biological function and chemical structure. Science. 1986; 233:532-534. (Pubitemid 16019904)
24. Massague J. The TGF-beta family of growth and differentiation factors. Cell. 1987;49:437-438.
25. Fischer JR, Darjes H, Lahm H, et al. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer. 1994;30A:2125-2129.
26. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factorbeta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86:1712-1719. (Pubitemid 29513039)
27. Ruffini PA, Rivoltini L, Silvani A, et al. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother. 1993;36:409-416. (Pubitemid 23146829)
28. Chen W, Wahl SM. TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 2003;14:85-89. (Pubitemid 36389522)
29. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772. (Pubitemid 32691889)
30. Enk AH, Jonuleit H, Saloga J, et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 1997; 73:309-316. (Pubitemid 27508890)
31. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860-1864. (Pubitemid 36460849)
32. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24:4721-4730. (Pubitemid 46630936)
33. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21: 624-630. (Pubitemid 46621895)
34. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:326-331. (Pubitemid 38256277)
35. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-smallcell lung cancer. Cancer Gene Ther. 2006;13:555-562.
36. Takahashi K, Shichijo S, Noguchi M, et al. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 1995;55:3478-3482.
37. Tomita Y, Kimura M, Tanikawa T, et al. Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol. 1993; 149:659-663. (Pubitemid 23094080)
38. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179:921-930. (Pubitemid 24065650)
39. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:8055-8062. (Pubitemid 41698748)
40. Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25:131-134. (Pubitemid 38019071)
41. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2007;25:7554.
42. Vansteenkiste JF, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2008;26:7501.
43. Ciardiello F, De Vita F, Orditura M, et al. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol. 2004;16:130-135. (Pubitemid 38402525)
44. Gonzalez G, Crombet T, Neninger E, et al. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin. 2007;3:8-13.
45. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26: 1452-1458.
46. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82:249-293. (Pubitemid 38209513)
47. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53: 641-651. (Pubitemid 23059449)
48. Rahn JJ, Chow JW, Horne GJ, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell-1. Clin Exp Metastasis. 2005;22:475-483. (Pubitemid 41750699)
49. Yin L, Li Y, Ren J, et al. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278:35458-35464. (Pubitemid 37102316)
50. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J BiolChem. 2004;279:45721-45727. (Pubitemid 39491562)
51. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163-175. (Pubitemid 38283802)
52. Reddish MA, MacLean GD, Poppema S, et al. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother. 1996;42:303-309. (Pubitemid 26281096)
53. Agrawal B, Krantz MJ, Reddish MA, et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4:43-49. (Pubitemid 28133078)
54. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23:6674-6681. (Pubitemid 46190262)
55. Butts C, Maksymiuk A, Goss G, et al. A multicentre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J Thorac Oncol. 2007;2:S332-S333.
56. Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26:4418-4425.
57. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751-761.
58. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother. 2004;53:275-306. (Pubitemid 38392306)
59. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-147. (Pubitemid 36287518)
60. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330-337. (Pubitemid 27303501)
61. Gatti E, Pierre P. Understanding the cell biology of antigen presentation: the dendritic cell contribution. Curr Opin Cell Biol. 2003;15:468-473. (Pubitemid 36928050)
62. Offringa R, van der Burg SH, Ossendorp F, et al. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol. 2000;12:576-582.
63. Babatz J, Rollig C, Lobel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55:268-276. (Pubitemid 41682575)
64. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98:8809-8814. (Pubitemid 32678109)
65. Itoh T, Ueda Y, Kawashima I, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother. 2002;51:99-106. (Pubitemid 34230724)
66. Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11: 3017-3024. (Pubitemid 40525207)
67. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999;5:1331-1338. (Pubitemid 29282936)
68. Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol. 2004;24:909-917.
69. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81. (Pubitemid 29265523)
70. Hirschowitz EA, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004;22: 2808-2815. (Pubitemid 41079898)
71. Hirschowitz EA, Foody T, Hidalgo GE, et al. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007;57:365-372. (Pubitemid 47285427)
72. Kontani K, Taguchi O, Ozaki Y, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003;12: 493-502.
73. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigenspecific immunotherapy in patients withMUC1-positive advanced cancer. J GeneMed. 2003;5:690-699. (Pubitemid 40309707)